by Raynovich Rod | Jan 18, 2016 | 2025 Rayno Biopharmaceuticals Portfolio
Valuation Models for Large Cap Biopharma Stocks Can Robust Drug Pipelines Deliver Future EPS Growth? This is a follow-up of our post on 1/8/16 Large Cap Biopharmaceuticals which looks at valuation models and stock performance of selected companies after the...
by Raynovich Rod | Oct 30, 2015 | Biopharmaceuticals
Biotech Innovation Seeks Value Healthcare Costs Mount The Bio Investor Forum has become a go-to meeting for biotech investors and company executives. Although the presenting companies are early stage or smaller cap public companies the attendees are broadly...
by Raynovich Rod | Sep 1, 2015 | Biopharmaceuticals
Update -2… 9/8 Rally Time Today Forecasted by Friday’s Action ETF Summary -One month and YTD % FBT (12.36), +9.2% IBB (8.9), +11.3% XBI (10.12), +17.27% The five star Fidelity Select Biotech Portfolio (FBIOX) pretty much tracks the IBB up 11.66% YTD and...
by Raynovich Rod | Aug 24, 2015 | Biopharmaceuticals
Nowhere to Hide in Another 4% Correction 8/25/15 Futures Look Promising at 11p EDT; NIKKEI 225 UP 4.8% Today’s market reached epic proportions of volatility and extremes exacerbated by a DOW opening “flash crash” off 1100 points that distorted faith...
by Raynovich Rod | Aug 21, 2015 | Biopharmaceuticals
At Close: IBB down 2.35% to 342 at May bottom, XBI up 0.64% to 218 —- Two Hours to Go 2:15p EDT, NASDAQ Down 1.79% at 4792, IBB at $349 Biotech Breakdown: Relief Today Or Another Head Fake? Biotech stocks are trying to hold the May lows with the IBB at $342 but...
by Raynovich Rod | Jul 30, 2015 | Biopharmaceuticals
Update-1 Stealth End of Month Rally Stops Biotech Slide IBB up 3.4% In July and up 1% on Last Day Stocks roared out of the box on Friday but could not hold and ended flat. NASDAQ Up 2.3% for July. Most biotech stocks were green and momentum players came back in to...
by Raynovich Rod | Jun 30, 2015 | 2025 Rayno Biopharmaceuticals Portfolio
Dealmaking and Fast Money Fuel Biotechs Q2 2015 Review Despite a major down trend at the end of April and the recent sell-off, the sector outperformed in Q2 of 2015. The S&P was down 1% and flat YTD. The XBI Biotech ETF continues to be the sector ETF leader up...
by Raynovich Rod | Jun 29, 2015 | Biopharmaceuticals
Biotech Stocks in Broad Sell-Off The biotech sector is usually immune to macro events but today the crisis in Greece gave investors an excuse to take profits. Many biotech stocks and ETFs were down over 3% faring worse than the NASDAQ down 2.4%. The sector, as tracked...
by Raynovich Rod | Jun 1, 2015 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Biotech Indices Can’t Break Through Triple Top IBB at $365, XBI at $239 Red and green day Biotech stocks were mixed today with the major indices holding the flat line. However with all of the clinical data coming out of ASCO (American Society for Clinical...
by Raynovich Rod | May 27, 2015 | Biopharmaceuticals
Update-1 Mixed Market but CAR-T stocks soar Biotechs could not break through the top today and were down about 0.5%. The XBI and XLV did a little better almost flat. Red and green were just about mixed among many stocks. Biomarin (BMRN) a “rare disease”...
